Adding head and neck cancer screenings to recommended lung cancer
screenings would likely improve early detection and survival, according
to a multidisciplinary team led by scientists affiliated with the
University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC
CancerCenter.
The team provides a
rationale for a national clinical trial to assess the effectiveness of
adding examination of the head and neck to lung cancer screening
programs. People most at risk for lung cancer are also those most at
risk for head and neck cancer.
"When caught early, the five-year survival rate for head and neck
cancer is over 83 percent," said senior author Brenda Diergaarde,
Ph.D., assistant professor of epidemiology at Pitt's Graduate School of
Public Health and member of the UPCI. "However, the majority of cases
are diagnosed later when survival rates generally shrink below 50
percent. There is a strong need to develop strategies that will result
in identification of the cancer when it can still be successfully
treated."
Head and neck cancer is the world's sixth-most common type of
cancer. Worldwide every year, 600,000 people are diagnosed with it and
about 350,000 die. Tobacco use and alcohol consumption are the major
risk factors for developing the cancer.
The early symptoms are typically a lump or sore in the mouth or
throat, trouble swallowing or a voice change, which are often brushed
off as a cold or something that will heal. Treatment, particularly in
later stages, can be disfiguring and can change the way a person talks
or eats.
Dr. Diergaarde and her team analyzed the records of 3,587 people
enrolled in the Pittsburgh Lung Screening Study (PLuSS), which consists
of current and ex-smokers aged 50 and older, to see if they had a higher
chance of developing head and neck cancer.
In the general U.S. population, fewer than 43 per 100,000 people
would be expected to develop head and neck cancer annually among those
50 and older. Among the PLuSS participants, the rate was 71.4 cases
annually per 100,000 people.
Recently, the U.S. Preventive Services Task Force, as well as the
American Cancer Society and several other organizations, recommended
annual screening for lung cancer with low-dose computed tomography in
people 55 to 74 years old with a smoking history averaging at least a
pack a day for a total of 30 years. The recommendation came after a
national clinical trial showed that such screening reduces lung cancer
mortality.
"Head and neck cancer is relatively rare, and screening the
general population would be impractical," said co-author David O.
Wilson, M.D., M.P.H., associate director of UPMC's Lung Cancer Center.
"However, the patients at risk for lung cancer whom we would refer for
the newly recommended annual screening are the same patients that our
study shows also likely would benefit from regular head and neck cancer
screenings. If such screening reduces mortality in these at-risk
patients, that would be a convenient way to increase early detection and
save lives."
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment